(This is associative evidence and may reflect confounding by indication, surveillance patterns, and glycaemic differences.) For post-marketing pharmacovigilance, FAERS-based analyses of semaglutide identify multiple safety signals (e.g., gastrointestinal obstruction-related terms, dehydration/volume depletion in some GLP-1RA analyses), but vulvovaginal dryness/infection/discharge/pain are not prominent as labelled risks in the major semaglutide FAERS disproportionality paper retrieved here
However, some symptoms may require immediate medical attention as they can cause more serious diseases or adverse events that need professional evaluation
Unlike injections, its a non-invasive method where the hormone is absorbed through the skin into the bloodstream, offering a steady release over time to address symptoms like fatigue, low libido, or muscle loss
I think theres really established precedent with regard to the compounding exception, which allows for this level of personalization that weve spoken about for patients that need it
The conversion is the same
